KWKatherine L. Webb

Katherine L. Webb

*This is an algorithmically generated author record based on publicly available information.

Katherine L. Webb has a total of 64 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Long-term SBP time in target and risk of cardiovascular events in older adults: a secondary analysis of the ASPREE cohort

    by Michael E Ernst, Katherine L Webb, Raj C Shah, Lawrence Beilin, Alice Owen, Suzanne G Orchard, Michelle A Fravel, Robyn L Woods, Mark R Nelson, Kevan R Polkinghorne, et al.

    Background: BP time in target range (TTR) predicts cardiovascular disease (CVD) in high-risk populations; however, TTR’s predictive utility in older adults without prior CVD is uncertain. Methods: We performed a post hoc analysis of the ASPirin in Reducing Events in the Elderly trial and its observational follow-up. SBP TTR for <140 and <130 mm Hg was estimated for each participant using BPs from the first 3 visits. Participants with 0% or 100% TTR were categorized separately, and remaining participants grouped into tertiles using linear interpolation to estimate TTR. Cox proportional hazards models evaluated associations between TTR and adjudicated incident CVD and major adverse cardiovascular events (MACE) after the TTR estimation period, with 0% TTR as reference. Results: Among 16,730 predominantly White Australian adults (mean age, 74 years) followed for a mean of 7.7 years after TTR estimation, 100% TTR <140 mm Hg had reduced risk of CVD (HR, 0.81; 95% CI, 0.68-0.96; P = .01), while 100% TTR <130 mm Hg had reduced risks of CVD (HR, 0.82; 95% CI, 0.67-0.99; P = .04) and MACE (HR, 0.72; 95% CI, 0.57-0.91; P < .01). Associations were strongest among women, antihypertensive users, frail/pre-frail participants, and those younger than median age. Findings were consistent after adjusting for competing risk of non-CVD death, when the TTR estimation period was extended an additional year, and when estimated using proportion of individual visit BPs at target. Conclusions: Longer SBP TTR was associated with reduced risk of cardiovascular events in older adults, underscoring the importance of sustained BP control with aging.


  • Open Access

    Late-life, visit-to-visit blood pressure variability and its association with sex-specific long-term cognitive outcomes

    by Michael E. Ernst, Kerry M. Sheets, Katherine L. Webb, Michelle A. Fravel, Robyn L. Woods, Lawrence Beilin, Suzanne G. Orchard, Raj C. Shah, Kevan R. Polkinghorne, Christopher M. Reid, et al.

    In 19 114 community-dwelling older adults enrolled in the ASPREE trial, high late-life visit-to-visit blood pressure variability (BPV) was associated with increased risks of incident dementia and cognitive decline during the median 4.7 year trial period. Whether sex or apolipoprotein E (ApoE) affect these associations over longer-term follow-up is unknown. We investigated the association between BPV and long term risks of dementia and cognitive decline using data from the ASPREE-eXTension (ASPREE-XT) study (median 8.3 year follow-up for dementia, 7.3 years for cognitive decline, after BPV estimation). Long-term BPV was estimated using standard deviation (SD) of the mean systolic BPs measured at ASPREE baseline, year 1 and 2 visits. Incident dementia was an adjudicated secondary endpoint and cognitive decline was defined as ≥1.5 SD decline in score from baseline sustained on the same of one, or more, standardized cognitive tests administered annually/biennially throughout ASPREE/ASPREE-XT. Analyses were stratified a priori by sex, using sex-specific SD tertiles of systolic BPV. Multivariable Cox proportional hazards regression comparing the highest BPV tertile to the lowest showed increased risk of dementia (HR = 1.33, 1.10–1.61) and cognitive decline (HR = 1.17, 1.06–1.30) in males, and cognitive decline in females (HR = 1.17, 1.07–1.28). In ApoE genotyped participants (81%), females in the highest BPV tertile lacking the ɛ4 allele had increased risk of dementia (HR = 1.39; 1.04–1.84), while risk of cognitive decline was increased in both sexes lacking the ɛ4 allele (males HR = 1.25; 1.09–1.43; females HR = 1.14; 1.01–1.29). These findings suggest both sex and ApoE impact the association of high BPV with long-term cognitive changes.

  • Open Access

    Obstructive sleep apnea and cerebral small vessel disease in community-based older people: an aspirin in reducing events in the elderly imaging substudy

    by Stephanie A Ward, Elsdon Storey, Matthew T Naughton, Rory Wolfe, Garun S Hamilton, Meng Law, Ryo Kawasaki, Walter P Abhayaratna, Katherine L Webb, Fergal J O’dOnoghue, et al.

    Study Objectives: Obstructive sleep apnea (OSA) may increase the risk of dementia. A potential pathway for this risk is through cerebral small vessel disease (CSVD). In the context of an existing randomized trial of aspirin for primary prevention, we aimed to investigate OSA’s impact on CSVD imaging measures and explore whether aspirin effects these measures over 3 years that differ in the presence or absence of OSA. Methods: A substudy of the aspirin in reducing events in the elderly (ASPREE) randomized placebo-controlled trial of low-dose aspirin. Community-dwelling participants aged 70 years and above, without cognitive impairment, cardiovascular disease, or known OSA completed an unattended limited-channel sleep study that calculated the oxygen desaturation index and apnea–hypopnea index. At baseline and 3 years later, volumes of white matter hyperintensities (WMH) and silent brain infarctions (SBI) were measured on 1.5 Tesla brain magnetic resonance imaging, and retinal vessel calibers were calculated from retinal vascular imaging. Results: Mild and moderate/severe OSA was detected in 48.9% and 29.9%, respectively, of the 311 participants, who had a mean age of 73.7 years (SD 3.4 years), 38.6% female. OSA of any severity was not associated with WMH volumes, SBI, nor retinal vessel calibers at baseline, nor with change in these measures in the 277 participants with repeated measures acquired after 3 years. OSA of any severity did not interact with aspirin on change in these measures over 3 years. Conclusions: In healthy older adults undiagnosed OSA was not associated with retinal vascular calibers and neuroimaging measures of CSVD. Clinical Trial Information: ASPREE trial has registration with the International Standard Randomized Controlled Trial Number (ISRCTN) www.isrctn.com, ISRCTN83772183 and with www.clinicaltrials.gov, NCT01038583. SNORE-ASA has registration with the Australian New Zealand Clinical Trials Registry (ANZCTR) at www.anzctr.org.au, ACTRN12612000891820.


  • Open Access

    Sleep apnoea, cognition and aspirin's effects in healthy older people: an ASPREE substudy

    by Stephanie A. Ward, Robyn L. Woods, Matthew T. Naughton, Rory Wolfe, Danijela Gasevic, Garun S. Hamilton, Walter P. Abhayaratna, Katherine Webb, Fergal J. O'DOnoghue, Nigel Stocks, et al.

    Importance: Obstructive sleep apnoea (OSA) may increase the risk of dementia; however, studies have reported variable findings. We investigated if undiagnosed OSA in healthy older adults is associated with cognitive decline, and whether low-dose aspirin could attenuate this.Methods: This was conducted as a substudy of the ASPirin in Reducing Events in the Elderly study. Participants were aged 70 years and above, free of dementia, cardiovascular disease and known OSA. A limited channel home sleep study calculated the oxygen desaturation index. Participants were randomised to daily aspirin 100 mg or placebo.Outcomes were the association of OSA, and the interaction of aspirin with OSA, with change in the Modified Mini-Mental State examination (3MS), a test of global cognition, over 3 years. Secondary outcomes were changes in domain-specific cognitive tests. Analyses were adjusted for relevant demographic, lifestyle and cardiometabolic factors.Results: Mild OSA, detected in 630 (49.0%) participants, and moderate/severe OSA, detected in 405 (31.5%) participants, were associated with lower 3MS scores over 3 years (mild OSA: β−0.58, 95% CI −1.15 to −0.00, p=0.049; moderate/severe OSA: β −0.69, 95% CI −1.32 to −0.05, p=0.035), compared to the 250 (19.5%) participants without OSA. No associations of OSA with decline in domain-specific cognitive tests were observed. Interaction terms were not significant for the effects of aspirin with OSA on change in any cognitive test score.Conclusions: OSA was associated with a small decline in global cognition over 3 years in this healthy older cohort. This decline was not attenuated by aspirin.


  • Open Access

    Expanded statistical analysis plan for legacy and long-term effects of aspirin in the ASPREE-XT observational follow-up study of participants in the ASPREE randomized trial

    by Rory Wolfe, Jonathan Broder, Andrew T Chan, Anne M Murray, Suzanne G Orchard, Galina Polekhina, Joanne Ryan, Andrew Tonkin, Katherine L Webb, Robyn L Woods

    The ASPREE randomized controlled trial (2010-2017) of 19,114 community-dwelling older adults without cardiovascular disease and significant disability compared daily 100mg aspirin to placebo. A total of 16,317 (93%) of 17,546 surviving and non-withdrawn participants agreed to continue regular study follow-up visits in the post-trial phase, named ASPREE-XT (2017-2024). We present a statistical analysis plan to underpin three main papers to report aspirin effects through to the fourth post-trial ASPREE-XT study visit with focus areas of: (1) death, dementia, and disability, (2) CVD events and bleeding, and (3) cancer. The focus of the plan is to estimate long-term (entire timespan of RCT plus post-trial) and legacy (post-trial period only) effects of aspirin in the setting of primary prevention for older individuals. Preliminary insights to these effects are presented that are based on data that has been reported to the study’s observational study monitoring board however formal data lock is not expected until October 2023.


  • Influence of Age, Sex, and Body Mass Index on the Depth of the Superficial Fascia in the Face and Neck

    by Gabriela Casabona, Konstantin Frank, Konstantin C. Koban, Thilo L. Schenck, Valeria P. Lopez, Katherine L. Webb, Hassan Hamade, David L. Freytag, Jeremy B. Green, Sebastian Cotofana

    BACKGROUND: Nonsurgical skin-tightening procedures are increasing in popularity, as patients seek aesthetic interventions that are safe with minimal downtime. OBJECTIVE: This study was designed to provide precise data on the depth of the superficial fascia—the structure of action—of the face and neck. METHODS: One hundred fifty Caucasian individuals (75 men and 75 women) were investigated with a balanced distribution of age (n = 30 per decade: 20–29, 30–39, 40–49, 50–59, and 60–69 years) and body mass index (BMI) (n = 50 per group: BMI ≤ 24.9 kg/m2, BMI between 25.0 and 29.9 kg/m2, and BMI ≥ 30 kg/m2). The distance between skin surface and the superficial fascia was measured through ultrasound in the buccal region, premasseteric region, and lateral neck. RESULTS: The mean distance between skin surface and superficial fascia was for the buccal region 4.82 ± 0.9 mm, range (2.60–6.90); for the premasseteric region 4.25 ± 0.6 mm, range (2.60–5.80); and for the lateral neck 3.71 ± 0.5 mm, range (2.0–5.0). The depth of the superficial fascia increased with increasing BMI, whereas it decreased with advanced age. CONCLUSION: Knowing the precise depth of the superficial fascia for nonsurgical skin-tightening procedures will guide practitioners toward safer and more effective outcomes.